Nucleated Red Blood Cell Emergence-Time in Newborn Lambs Following a Dose of Darbepoetin Alfa.

Nucleated red blood cells darbepoetin erythropoietin dosing gestational age newborn lambs platelets or leukocytes

Journal

Current pediatric reviews
ISSN: 1875-6336
Titre abrégé: Curr Pediatr Rev
Pays: United Arab Emirates
ID NLM: 101240290

Informations de publication

Date de publication:
2023
Historique:
received: 02 12 2022
accepted: 13 12 2022
pubmed: 21 12 2022
medline: 9 2 2023
entrez: 20 12 2022
Statut: ppublish

Résumé

Nucleated red blood cells (NRBC) are very uncommon in the blood of children and adults, but small numbers are not rare in neonates on the day of birth. Elevated NRBC counts in neonates can be seen following erythropoietin dosing. Limited studies in human neonates suggest the time-interval between erythropoietin dosing and the first appearance of NRBC in the blood (the "NRBC emergence-time") is in excess of 24 hours. We made serial blood counts (Sysmex veterinary analyzer) on ten newborn lambs; five were dosed with darbepoetin (10 μg/kg), and five were dosed with a vehicle-control to assess the NRBC emergence time under relatively controlled laboratory conditions. The first appearance of NRBC was at 24 h (2757 ± 3210 NRBC/μL vs. 0/μL in controls). Peak was 48-72 h (16,758 ± 8434/μL vs. 0/μL in controls), followed by fewer at 96 hours (7823 ± 7114/μL vs. 0/μL in controls). Similarly, reticulocytes peaked at 48-72 h (113,094 ± 3210/μL vs. 10,790 ± 5449/μL in controls), with no changes in platelets or leukocytes. The NRBC emergence time in newborn lambs is similar to reports from newborn humans. By extrapolation, if a neonate has a high NRBC at birth, the erythropoietic stimulus likely occurred within the interval 24 to perhaps 96+ hours prior to birth.

Sections du résumé

BACKGROUND BACKGROUND
Nucleated red blood cells (NRBC) are very uncommon in the blood of children and adults, but small numbers are not rare in neonates on the day of birth. Elevated NRBC counts in neonates can be seen following erythropoietin dosing. Limited studies in human neonates suggest the time-interval between erythropoietin dosing and the first appearance of NRBC in the blood (the "NRBC emergence-time") is in excess of 24 hours.
METHODS METHODS
We made serial blood counts (Sysmex veterinary analyzer) on ten newborn lambs; five were dosed with darbepoetin (10 μg/kg), and five were dosed with a vehicle-control to assess the NRBC emergence time under relatively controlled laboratory conditions.
RESULTS RESULTS
The first appearance of NRBC was at 24 h (2757 ± 3210 NRBC/μL vs. 0/μL in controls). Peak was 48-72 h (16,758 ± 8434/μL vs. 0/μL in controls), followed by fewer at 96 hours (7823 ± 7114/μL vs. 0/μL in controls). Similarly, reticulocytes peaked at 48-72 h (113,094 ± 3210/μL vs. 10,790 ± 5449/μL in controls), with no changes in platelets or leukocytes.
CONCLUSION CONCLUSIONS
The NRBC emergence time in newborn lambs is similar to reports from newborn humans. By extrapolation, if a neonate has a high NRBC at birth, the erythropoietic stimulus likely occurred within the interval 24 to perhaps 96+ hours prior to birth.

Identifiants

pubmed: 36537595
pii: CPR-EPUB-128317
doi: 10.2174/1573396319666221219153902
doi:

Substances chimiques

Darbepoetin alfa 15UQ94PT4P
Erythropoietin 11096-26-7

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

425-428

Informations de copyright

Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Auteurs

Timothy M Bahr (TM)

Division of Neonatology, Department of Pediatrics, University of Utah Health, Salt Lake City, Utah, UT 84132, USA.
Women and Newborn's Research, Intermountain Healthcare, Salt Lake City, Utah, UT 84132, USA.
Division of Neonatology, Utah Valley Hospital, Provo, UT 84132, USA.

Kurt H Albertine (KH)

Division of Neonatology, Department of Pediatrics, University of Utah Health, Salt Lake City, Utah, UT 84132, USA.

Robert D Christensen (RD)

Division of Neonatology, Department of Pediatrics, University of Utah Health, Salt Lake City, Utah, UT 84132, USA.
Women and Newborn's Research, Intermountain Healthcare, Salt Lake City, Utah, UT 84132, USA.
Division of Hematology/Oncology, University of Utah Health, Salt Lake City, Utah, UT 84132, USA.

Mar Janna Dahl (MJ)

Division of Neonatology, Department of Pediatrics, University of Utah Health, Salt Lake City, Utah, UT 84132, USA.

Andrew Rebentisch (A)

University of Utah Student in Dr. Albertine's Laboratory, Salt Lake City, Utah, UT 84132, USA.

Elaine Dawson (E)

University of Utah Student in Dr. Albertine's Laboratory, Salt Lake City, Utah, UT 84132, USA.

Emily Major (E)

University of Utah Student in Dr. Albertine's Laboratory, Salt Lake City, Utah, UT 84132, USA.

Hannah Foreman (H)

University of Utah Student in Dr. Albertine's Laboratory, Salt Lake City, Utah, UT 84132, USA.

David Headden (D)

University of Utah Student in Dr. Albertine's Laboratory, Salt Lake City, Utah, UT 84132, USA.

Zoë Vordos (Z)

University of Utah Student in Dr. Albertine's Laboratory, Salt Lake City, Utah, UT 84132, USA.

Akbarali Nabi (A)

University of Utah Student in Dr. Albertine's Laboratory, Salt Lake City, Utah, UT 84132, USA.

Luke Pettet (L)

University of Utah Student in Dr. Albertine's Laboratory, Salt Lake City, Utah, UT 84132, USA.

Peter Badrov (P)

University of Utah Student in Dr. Albertine's Laboratory, Salt Lake City, Utah, UT 84132, USA.

Connor Addison (C)

University of Utah Student in Dr. Albertine's Laboratory, Salt Lake City, Utah, UT 84132, USA.

Daniel R Christensen (DR)

University of Utah Student, Salt Lake City, Utah, UT 84132, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH